Last update 01 Nov 2024

Surface Logix, Inc.

Private Company|

United States

Private Company|

United States

Last update 01 Nov 2024

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with Surface Logix, Inc.

EUCTR2007-001668-62-DE / Not yet recruitingNot Applicable

A pilot Phase IIa, randomised, double blind, placebocontrolled, crossover study to examine the safety, tolerability and pharmacodynamic effects on blood pressure of repeat oral doses of SLx-2101 5 mg or 10 mg once daily for up to 14 days in patients with hypertension.

Start Date25 Jun 2007

Sponsor / Collaborator

Surface Logix, Inc.

EUCTR2007-000320-40-GB / Not yet recruitingPhase 2

A pilot Phase IIa randomised, double blind, placebo-controlled, crossover study to examine the safety, tolerability and pharmacodynamic effects on blood pressure of repeat oral doses of SLx-2101 5, 10 or 20 mg once daily for up to 14 days in patients with hypertension.

Start Date14 Jun 2007

Sponsor / Collaborator

Surface Logix, Inc.

EUCTR2007-000397-23-DE / Not yet recruitingNot Applicable

A randomised, double blind, placebo-controlled, cross-over pilot study to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days in patients with secondary Raynaud’s disease.

Start Date29 May 2007

Sponsor / Collaborator

Surface Logix, Inc.

100 Clinical Results associated with Surface Logix, Inc.

0 Patents (Medical) associated with Surface Logix, Inc.

Literatures (Medical) associated with Surface Logix, Inc.

01 Feb 2012·Stroke

Abstract 3576: Selective Inhibition Of Rho-kinase Type 2 In Ischemic Stroke

Author: Sweetnam, Paul ; Tong, Warwick ; Yi, Zheng ; Lee, Jeong Hyun ; Ayata, Cenk ; Schueller, Olivier

Background and aims: Rho/Rho-associated protein kinase (ROCK) pathway plays a pivotal role in the pathogenesis of vascular diseases including stroke. Indeed, ROCK inhibitors improve cerebral blood flow in ischemic brain, and are neuroprotective in a variety of experimental ischemia models. Evidence suggests that ROCK type 2 (ROCK2) is more relevant in acute stroke treatment. We tested the neuroprotective efficacy and safety of a novel selective small-molecule ROCK2 inhibitor, SLx-2119, in ischemic stroke, and characterized the dose-response and therapeutic window. Methods and results: All experiments were conducted by a blinded investigator. Mice were anesthetized with isoflurane (2.5% induction, 1.2% maintenance, in 70% N2O/30% O2), and subjected to 1h transient middle cerebral artery occlusion (MCAO) using an intraluminal filament inserted via the external carotid artery. Regional CBF was monitored using a laser Doppler probed placed over the core MCA territory. Neurological deficits were assessed before sacrifice at 48h, using five-point grading. Indirect infarct volumes were calculated using 1mm-thick TTC-stained coronal sections. SLx-2119 (50-300 mg/kg) or vehicle was administered via orogastric gavage (in 0.4% methylcellulose) every 12h until 48h after reperfusion. When started 24h before MCAO (pre-ischemic treatment), SLx-2119 produced a dose-dependent decrease in infarct volume (37% decrease at 200 mg/kg and 26% decrease at 100 mg/kg) compared to vehicle treated group. Post-ischemic treatment with SLx-2119 (200 mg/kg) remained efficacious when initiated 1h (34% decrease in infarct volume) or 3h (21% decrease in infarct volume), but not 6h after MCAO, suggesting a therapeutic window between 3-6h after stroke onset in mice. SLx-2119 also improved neurological deficits, but did not alter CBF reduction in the ischemic core, systemic arterial pressure, pH or blood gas values, or mortality. Conclusions: These data suggest that selective ROCK2 inhibition improves tissue and neurological outcome in acute stroke, with an efficacy comparable to that previously reported for non-selective ROCK inhibitors. Unlike non-selective ROCK inhibitors, ROCK2 inhibition does not precipitate hypotension, an important dose-limiting side effect in acute stroke.

01 Jun 2011·Journal of Pharmacology and Experimental TherapeuticsQ3 · MEDICINE

A Small-Molecule Inhibitor of Enterocytic Microsomal Triglyceride Transfer Protein, SLx-4090: Biochemical, Pharmacodynamic, Pharmacokinetic, and Safety Profile

Q3 · MEDICINE

Article

Author: Schueller, Olivier ; Sweetnam, Paul ; Kuo, Jay ; Kim, Enoch ; Ferkany, John ; Cole, Bridget ; Ellis, James ; Wong, Eric ; Campbell, Stewart

First-generation microsomal triglyceride transfer protein (MTP) inhibitors were designed to inhibit hepatic MTP and provide a novel treatment of dyslipidemia. Effective at lowering low-density lipoprotein-cholesterol (LDL-C), these inhibitors also elevate liver enzymes and induce hepatic steatosis in animals and humans. MTP is highly expressed in the enterocytes, lining the lumen of the jejunum, and is critical in the production of chylomicrons assembled from lipid/cholesterol and their transfer into systemic circulation. 6-(4'-Trifluoromethyl-6-methoxy-biphenyl-2-ylcarboxamido)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid phenyl ester (SLx-4090) (IC(50) value ∼8 nM) was designed to inhibit only MTP localized to enterocytes. In Caco-2 cells SLx-4090 inhibited apolipoprotein B (IC(50) value ∼9.6 nM) but not apolipoprotein A1 secretion. Administered orally to rats SLx-4090 reduced postprandial lipids by >50% with an ED(50) value ∼7 mg/kg. SLx-4090 was not detected in the systemic or portal vein serum of the animals (lower limit of quantitation ∼5 ng/ml) after single or multiple oral doses in fasted rodents. When coadministered with tyloxapol, SLx-4090 did not inhibit the secretion of hepatic triglycerides (TG), consistent with the absence of systemic exposure. Chronic treatment with SLx-4090 in mice maintained on a high-fat diet decreased LDL-C and TG and resulted in weight loss without the elevation of liver enzymes or an increase in hepatic fat. The compound did not result in toxicity when administered to rats for 90 days at a dose of 1000 mg/kg per day. These data support the concept that the inhibition of enterocytic MTP could serve as a useful strategy in the treatment of metabolic disorders.

01 Oct 2008·Blood Coagulation & FibrinolysisQ4 · MEDICINE

Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin

Q4 · MEDICINE

Article

Author: Paul Sweetnam ; Qiang Fu ; Louis M. Fink ; James L. Ellis ; Martin Hauer-Jensen ; Sharon McGonigle ; Junru Wang ; David S Loose ; Marjan Boerma ; Elsa Paradise ; Alessandra Bartolozzi ; Marie Catherine Vozenin-Brotons

Inhibitors of Rho kinase (ROCK) are a relatively new class of drugs with potential benefits in oncology, neurology, and fibrotic and cardiovascular diseases. ROCK inhibitors modulate many cellular functions, some of which are similar to the pleiotropic effects of statins, suggesting additive or synergistic properties. Studies to date have used compounds that inhibit both isoforms of ROCK, ROCK1 and ROCK2. This study was designed to compare gene expression profiles of atorvastatin with the newly developed ROCK2 inhibitor SLx-2119 in primary cultures of normal human endothelial cells, smooth muscle cells, and fibroblasts. Cells were treated with each compound for 24 h, after which total RNA was isolated and genome-wide gene-expression profiles were obtained with Illumina arrays. Because of the known effect of statins on the actin cytoskeleton and on connective tissue growth factor, a prominent growth factor involved in tissue fibrosis, the effects of SLx-2119 and atorvastatin on the actin cytoskeleton and connective tissue growth factor mRNA were also examined in cultures of smooth muscle cells with a fibrotic phenotype, isolated from biopsies of human intestine with radiation-induced fibrosis. Although SLx-2119 and atorvastatin affected expression of genes belonging to the same biological processes, individual genes were mostly different, consistent with synergistic or additive properties. Both SLx-2119 and atorvastatin reduced connective tissue growth factor mRNA and remodeled the actin cytoskeleton in fibrosis-derived smooth muscle cells, suggesting that both compounds have antifibrotic properties. These results form the basis for further studies to assess the possible therapeutic benefit of combined treatments.

100 Deals associated with Surface Logix, Inc.

100 Translational Medicine associated with Surface Logix, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 24 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Surface Logix, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 24 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing